Phytomedicine Plus (Nov 2022)

Isolation and in vivo evaluation of anti-breast cancer activity of resin glycoside merremoside from Ipomoea aquatica Forsskal in overcoming multi-drug resistance

  • M Sasikala,
  • S Mohan,
  • S Swarnakumari,
  • A Nagarajan

Journal volume & issue
Vol. 2, no. 4
p. 100359

Abstract

Read online

Purpose: Ipomoea aquatica belongs to convulvulaceae family and finds use in various ailments including anticancer activity. A secondary metabolite merromoside (a resin glycoside) isolated from this plant is evaluated for anti-breast cancer activity through in vivo studies. Methods: The Extract of the whole plant has been prepared by maceration method using 50%v/v ethanol in distilled water to get a hydroalcoholic extract. The phytochemical evaluation reveals that the active secondary metabolite was isolated by using column chromatographic technique. The isolated compound was evaluated for its anticancer properties through invivo method using 7,12-Dimethylbenz[a]anthracene induced mice models. Results: The isolated compound (W04) from the plant extract was found to have a significant enzymatic antioxidant effects and percentage reduction of tumour cells of DMBA induced breast tissue of Sprague dawley rats. Conclusion: The isolated compound merromoside from hydroalcoholic extract of Ipomoea aquatica has been evaluated for anti-breast cancer properties. The down regulation of inflammatory cytokines, P-gp efflux & ROS species will prevent reverse signalling and angiogenesis. This indicates that merromoside isolated from Ipomoea aquatica will overcome MDR (multi-drug resistance) in breast cancer especially DOX-resistant (Doxorubicin) and also it will be further used to develop drug formulations in order to overcome world challenges in cancer treatment

Keywords